CanariaBio
CanariaBio is a South Korea-based, KOSDAQ-listed clinical-stage biopharmaceutical company developing first-in-class tumor antigen-specific monoclonal antibody immunotherapies, primarily Oregovomab for ovarian cancer and AR20.5 (BrevaRex) for pancreatic cancer.
- Company typePublic
- Founded2000
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CanariaBio does
CanariaBio (카나리아바이오, Canariabio Inc.) is a South Korea-based clinical-stage biopharmaceutical company focused on developing tumor antigen-specific monoclonal antibody immunotherapies for cancers with high unmet medical need. The company's core technology platform comprises a portfolio of monoclonal immunoglobulins targeting four tumor antigens — CA-125, MUC1, PSA, and Her2/neu — with two lead product candidates: Oregovomab, a first-in-class anti-CA-125 monoclonal antibody in global Phase III development (FLORA-5) for newly diagnosed and recurrent ovarian cancer, the deadliest gynecologic malignancy; and AR20.5 (BrevaRex), an anti-MUC1 monoclonal antibody that has completed Phase 1 for pancreatic cancer. The company previously listed on KOSDAQ (ticker 016790) in March 2022 and operates additional programs in FLORA-4 (Oregovomab + Niraparib combination Phase II) and FLORA-6 (Phase II).
The company's business model is pre-revenue: it generates no commercial product sales, has no distribution channels, and has not publicly disclosed pricing. Revenue mechanics, if/when Oregovomab is approved, would follow a traditional biopharmaceutical licensing/commercialization model, with regional partners already referenced (Specialised Therapeutics referenced via family-site links; co-development with Canada's OncoQuest). The company has experienced severe financial distress: in January 2024, the DSMB recommended discontinuation/monitoring of the Oregovomab Phase III trial, leading to capital impairment, a rejected 2023 audit opinion, and KOSDAQ trading suspension. In May 2024, the bio business was spun off into a new subsidiary, OcupeBio Inc. (오큐피바이오), with approximately KRW 267.6 billion in associated debt transferred, and a KRW 120 billion rights offering was launched in November 2024 to fund the continuation of FLORA-5. The company continues to operate through the listed entity and its biopharmaceutical subsidiary, with ongoing clinical follow-up monitoring of completed Oregovomab patients.
CanariaBio firmographics
Firmographics- Name
- CanariaBio
- Legal name
- Canariabio Inc.
- Website
- https://canariabio.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CanariaBio is a South Korea-based, KOSDAQ-listed clinical-stage biopharmaceutical company developing first-in-class tumor antigen-specific monoclonal antibody immunotherapies, primarily Oregovomab for ovarian cancer and AR20.5 (BrevaRex) for pancreatic cancer.
- Ownership category
- akta.pro rank
CanariaBio industry classification
Industry- Product category
- Cancer Immunotherapy Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where CanariaBio is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
CanariaBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Others
Marketing channels3 records
CanariaBio product offering
Product offeringCore offering
CanariaBio is a Korean biopharmaceutical company developing tumor antigen specific monoclonal antibody immunotherapies for cancers with high unmet medical needs. Its lead product, Oregovomab, is a first-in-class monoclonal antibody targeting CA-125 for ovarian cancer and is in global Phase III clinical trials. A second pipeline candidate, AR20.5 (BrevaRex), targets MUC1 for pancreatic cancer treatment and is in Phase 1/2 development.
Product overview
CanariaBio is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. The company's portfolio includes Oregovomab as the flagship first-in-class ovarian cancer immunotherapy product undergoing global Phase III trials, and AR20.5 (BrevaRex) targeting pancreatic cancer in Phase 1/2 development. These are supported by a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu antigens.
Differentiator
Problem solved
Functional benefit
Brands
- Oregovomab: First-in-class immunotherapy for ovarian cancer - flagship product undergoing global Phase III clinical trial
- BrevaRex (MAb-AR20.5)
Products and services
- Oregovomab First-in-class monoclonal antibody immunotherapy targeting CA-125 tumor antigen for ovarian cancer. Designed for patients with newly diagnosed and recurrent ovarian cancer. Currently in global Phase III clinical trials (FLORA-5) conducted at 163 sites across 16 countries.
- BrevaRex (MAb-AR20.5) Monoclonal antibody targeting MUC1 for pancreatic cancer treatment. Phase 1 completed with Phase 2 planned. Addresses pancreatic cancer, which accounts for approximately 7% of all cancer deaths.
Companies that use CanariaBio
Customer profileSegments1 record
Ideal customer profiles2 records
CanariaBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CanariaBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- OncoQuest (Canada)coreCanadian biotech company that led the successful Phase II clinical trial. OncoQuest clinical team is leading the review of Phase III continuation decisions following DSMB recommendations. Partnership involves co-development of Oregovomab immunotherapy for ovarian cancer.
Scale indicators5 records
Recent moves12 records
Expansion highlights6 records
CanariaBio competitors and assessment
Company assessmentDirect peers
- MacroGenics: Clinical-stage biotechnology company developing monoclonal antibody-based therapeutics for cancer, including programs targeting solid tumors — directly comparable as a focused oncology mAb developer with platform technology.
- Clovis Oncology: Developed Rubraca (rucaparib) for ovarian cancer; comparable as a focused ovarian cancer therapeutics developer that experienced commercial and clinical setbacks — relevant cautionary parallel.
- ImmunoGen: Developed mirvetuximab soravtansine, a first-in-class FRα-targeted antibody-drug conjugate for ovarian cancer — the most directly comparable antibody-based ovarian cancer therapeutic developer, recently acquired by AbbVie.
Emerging players
- OncoQuest (Canada): Canadian biotech that led the Phase II trial of Oregovomab and is the strategic co-development partner for the Phase III program; directly comparable as a clinical-stage oncology mAb developer and CanariasBio's closest operational peer.
Broad incumbents
- Bristol-Myers Squibb: Major immuno-oncology player with Opdivo (nivolumab) and Yervoy (ipilimumab); comparable as a developer of monoclonal antibody-based cancer immunotherapy across multiple solid tumor indications.
- AstraZeneca: Major oncology incumbent with Lynparza (olaparib) as a leading ovarian cancer therapy and a broad immuno-oncology pipeline; comparable as a competitor in ovarian cancer treatment and a developer of biologic cancer therapeutics.
- Merck & Co. Leader in immuno-oncology with Keytruda (pembrolizumab); comparable as a developer and commercializer of cancer immunotherapy including ovarian cancer indications where PD-1/PD-L1 mechanisms compete with novel mAb approaches.
- GSK: Major oncology player with ovarian cancer therapy Zejula (niraparib) and a growing immuno-oncology pipeline; comparable as a competitor in ovarian cancer treatment and as a developer of antibody-based cancer therapeutics.
- Genentech (Roche): Pioneer and global leader in monoclonal antibody therapeutics for oncology, including Her2/neu-targeted agents (Herceptin) that overlap with CanariasBio's platform targets — comparable as both a direct and adjacent competitor in mAb cancer therapy.
Regional players
- Specialised Therapeutics: Listed as a family-site partner on CanariasBio's website, indicating a regional distribution/co-development relationship for Oregovomab; comparable as a specialty oncology partner with geographic overlap in Asian/Pacific markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
CanariaBio social profiles
Digital presenceCanariaBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
CanariaBio leadership team
Management profileNumber of profiles
Profiles1 record
CanariaBio subsidiaries and ownership
Company hierarchySubsidiaries2 records
CanariaBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CanariaBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CanariaBio
What does CanariaBio do?
CanariaBio is a Korean biopharmaceutical company developing tumor antigen specific monoclonal antibody immunotherapies for cancers with high unmet medical needs. Its lead product, Oregovomab, is a first-in-class monoclonal antibody targeting CA-125 for ovarian cancer and is in global Phase III clinical trials. A second pipeline candidate, AR20.5 (BrevaRex), targets MUC1 for pancreatic cancer treatment and is in Phase 1/2 development.
Is CanariaBio a public or private company?
CanariaBio is a public company. It is classified as public and is currently operating.
When was CanariaBio founded?
CanariaBio was founded in 2000. It employs 11 to 50 people.
Where is CanariaBio based?
CanariaBio is headquartered in Seoul, South Korea, in the Asia region.
Who are CanariaBio's main competitors?
Direct peers on record are MacroGenics, Clovis Oncology and ImmunoGen. OncoQuest (Canada) is listed as an emerging player. Broad incumbents are Bristol-Myers Squibb, AstraZeneca, Merck & Co., GSK and Genentech (Roche). Specialised Therapeutics is listed as a regional player.
Does CanariaBio have an API?
No public API is recorded for CanariaBio.
What industry is CanariaBio in?
CanariaBio's product category is Cancer Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2833.